Literature DB >> 8452480

Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens.

P Hirsimäki1, Y Hirsimäki, L Nieminen, B J Payne.   

Abstract

The effects of equimolar doses of the triphenylethylene antiestrogens tamoxifen and toremifene on female Sprague-Dawley rat liver were studied in a 52-week toxicity study which included a 13-week recovery period. Liver tumors were found in four out of five rats at the highest dose level of tamoxifen (45 mg/kg per day) after 52 weeks of dosing, and these appeared to be hepatocellular carcinomas in three rats. After the 13-week recovery period all surviving rats in the highest tamoxifen dose group had large liver tumors (diameter up to 2 cm) which appeared to be hepatocellular carcinomas in five out of six rats. No tumor was observed in the toremifene-treated rats (48 mg/kg per day) either after 52 weeks of dosing or after the recovery period. Electron microscopic morphometric analysis after 52 weeks of dosing revealed that at the tamoxifen high dose level, the volume densities of the peroxisomes, mitochondria, and residual bodies were elevated in the nonneoplastic hepatocytes of the rats. In the neoplastic hepatocytes of the tamoxifen-treated rats the volume density of nuclei was slightly elevated. The slight proliferation of peroxisomes and mitochondria might be related to tumor development in the tamoxifen treated rats.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452480     DOI: 10.1007/bf02072035

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  6 in total

1.  Conjugated oestrogens.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risk Chem Hum       Date:  1979-12

Review 2.  The pharmacology and clinical uses of tamoxifen.

Authors:  B J Furr; V C Jordan
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

3.  Induction and promotion of gamma-glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations.

Authors:  M Ghia; E Mereto
Journal:  Cancer Lett       Date:  1989-08       Impact factor: 8.679

4.  Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.

Authors:  E di Salle; T Zaccheo; G Ornati
Journal:  J Steroid Biochem       Date:  1990-06-22       Impact factor: 4.292

Review 5.  Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

6.  Promotive effects of steroids and bile acids on hepatocarcinogenesis initiated by diethylnitrosamine.

Authors:  R G Cameron; K Imaida; H Tsuda; N Ito
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

  6 in total
  11 in total

Review 1.  Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.

Authors:  J U Mäenpää; S L Ala-Fossi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

Review 2.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 3.  Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.

Authors:  M G Curtis
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 4.  Toremifene in the treatment of breast cancer.

Authors:  Mika Vj Mustonen; Seppo Pyrhönen; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 5.  Tamoxifen and secondary tumours. An update.

Authors:  N Wilking; E Isaksson; E von Schoultz
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

6.  Species differences in the metabolic activation of tamoxifen into genotoxic derivatives: risk assessment in women.

Authors:  F De Matteis; I N White; L L Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

7.  Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats.

Authors:  Y P Dragan; S Fahey; K Street; J Vaughan; V C Jordan; H C Pitot
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver.

Authors:  F Montandon; G M Williams
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

9.  Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.

Authors:  S Pyrhönen; R Valavaara; H Modig; M Pawlicki; T Pienkowski; S Gundersen; J Bauer; G Westman; S Lundgren; G Blanco; O Mella; I Nilsson; T Hietanen; I Hindy; J Vuorinen; A Hajba
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 10.  Selective estrogen receptor modulators: tissue specificity and clinical utility.

Authors:  Stephen Martinkovich; Darshan Shah; Sonia Lobo Planey; John A Arnott
Journal:  Clin Interv Aging       Date:  2014-08-28       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.